<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090075</url>
  </required_header>
  <id_info>
    <org_study_id>21183-01</org_study_id>
    <nct_id>NCT02090075</nct_id>
  </id_info>
  <brief_title>Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque</brief_title>
  <official_title>Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin K-antagonists (VKA) such as warfarin are the most widely used blood thinners for
      irregular heart beats like atrial fibrillation. Several lines of evidence indicate, however,
      that these agents also cause calcification of vessels (hardening of the vessels). Vascular
      calcification is one of the recently revealed side-effects of warfarin therapy. We will be
      randomizing 66 patients to either take warfarin or a new blood thinner that works without
      affecting vitamin k (apixaban). Patients will undergo blood testing and a CT angiogram
      (non-invasive angiogram) at the beginning of the study, and then be followed for one year
      with quarterly visits including blood tests and given either warfarin or vitamin K. After one
      year, they will undergo another CT angiogram and examination and blood tests and the effect
      of apixaban and warfarin are tested to look at plaque and changes over time. Patients will be
      consented in a private room and the risks and benefits will be explained. The risks include
      the CT angiogram and the possibility of either remaining on warfarin therapy for another year
      (standard of care) or taking a medicine that doesn't require monitoring (apixaban) for one
      year. The CT angiograms will require some contrast and some radiation dose, which will be
      minimized as much as possible. A cardiologist will be present during each CT angiogram to
      minimize risk and ensure patient safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The progression of atherosclerotic plaques characterized by various anatomic plaque
      composition changes has been acknowledged to be associated with increased plaque rupture,
      myocardial infarction and death. Coronary computed tomography angiography (CCTA) has emerged
      as a novel non-invasive modality with high diagnostic performance for detection and
      assessment of atheroma compared to invasive coronary angiography (ICA) and intravascular
      ultrasound (IVUS). Beyond stenosis severity, CCTA also permits anatomic quantification of
      numerous atheroscleroticStudy design This is a prospective, single-centered, randomized,
      open-label trial with blinded adjudication of results (plaque composition) designed to
      compare apixaban (2.5 mg or 5 mg BID per the current guideline) with warfarin (target
      international normalized ratio, 2.0 to 3.0) for 52 weeks on calcified plaque, coronary plaque
      composition and volume in patients with non-valvular AF.

      Study population The targeted population included patients aged 18-84 years with non-valvular
      AF or flutter at enrollment or two more episodes of AF (as documented by electrocardiography)
      at least 2 weeks apart in the 12 months before enrollment. The inclusion and exclusion
      criteria were shown in detail in a recent paper. Subjects were enrolled from May 2014 to
      December 2015 and randomized into warfarin group (VKA_group) or apixaban group (Api_group).
      Of the 66 originally enrolled patients, 56 had complete data at final follow-up, including
      interpretable CCTA scans at baseline and follow-up. All subjects were followed up for a total
      52 weeks.

      Coronary CTA scan protocol All CT scans were performed with a 64-slice CT scanner (Lightspeed
      VCT; General Electric Healthcare Technologies, Milwaukee, WI, USA), or 256-slice CT scanner
      (Revolution CT; General Electric Healthcare Technologies, Milwaukee, WI, USA). Before CCTA, a
      prospective non-enhanced coronary calcium (CAC) scan was performed. For quantitative
      assessment of CAC, the Agatston score was calculated, using a 3 mm CT slice thickness and a
      detection threshold of ≥130 HU involving ≥1 mm2 area/lesion (3 pixels). CCTA was performed
      using a collimation of 64 × 0.625 mm or 256 × 0.625 mm and a rotation time of 0.4 s or 0.28
      s. The tube current was 400-770 mA (depending on body weight), at 100-120 kV. Contrast
      material at a flow rate of 5.0 mL/s was administered in the antecubital vein, with volumes
      depending on the total scan time (60-80 mL). In the absence of contraindications, patients
      with a heart rate ≥60 bpm were administered 50-100 mg metoprolol oral and up to 40 mg
      metoprolol intravenous if needed. Interpretation was performed by expert reading by an
      experienced cardiologist (M.J.B) blinded to all clinical data.

      plaque phenotypes, plaque burden and ability to differentiate between various plaque types.
      Also, recent technology providing low radiation dose for CCTA with approximately &lt; 1-3mSv
      allows us to investigate the effects of different therapies using serial CCTA.

      Warfarin, a vitamin K antagonist (VKA) and one of the most commonly used oral
      anti-coagulants, has been showed to increase vascular calcification leading to increased
      cardiovascular (CV) events. However, apixaban, a direct Factor Xa inhibitor, has no
      interaction with vitamin K and its effect on the progression of atherosclerotic plaques is
      still unknown. The potential benefit of avoiding VKA therapy and the favorable effects of
      factor Xa inhibitors may contribute to a reduction in CV events. We aimed to compare apixaban
      with warfarin on progression of coronary plaque composition and volume in non-valvular AF
      patients using CCTA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 5, 2017</completion_date>
  <primary_completion_date type="Actual">December 27, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Artery Calcium (CAC) Score</measure>
    <time_frame>1 year</time_frame>
    <description>amount of calcification measured by Agatston Score. The range of values for the Agatston score is 0-10000. Higher score is worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary Plaque on CT Angiography</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate if treatment with apixaban therapy, as compared to warfarin therapy, will modify the progression, regression and stabilization of coronary atherosclerosis. Modifications will include differences in plaque volume, composition and arterial remodeling; as well as new atherosclerosis formation. The scale is based upon volume of plaque in the coronary arteries, with zero being no plaque and a higher number being more plaque. There is no scale or maximum measure, this is a linear measure of atherosclerosis volume in the coronary arteries and more is worse. None is best, any plaque is considered worse, and a higher plaque volume represents more atherosclerosis. An individual of average health will have a score of 50.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>apixaban 5 mg or 2.5 mg po bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>warfarin with target INR of 2-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apixaban</intervention_name>
    <description>5 po or 2.5 po bid.</description>
    <arm_group_label>apixaban</arm_group_label>
    <other_name>eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <arm_group_label>warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible patients with atrial fibrillation or flutter

          -  Age 18-84 years

          -  Willingness to participate in the study and ability to sign informed consent.

        Exclusion Criteria:

          -  Atrial fibrillation due to a reversible cause

          -  moderate or severe mitral stenosis

          -  conditions other than atrial fibrillation that require anticoagulation (e.g., a
             prosthetic heart valve)

          -  A need for aspirin at a dose of &gt;165 mg a day or for both aspirin and P2Y-inhibitor

          -  Serious bleeding event in the previous 6 months or a high risk of bleeding (eg, active
             peptic ulcer disease)

          -  a platelet count of &lt;100,000/mm3 or hemoglobin level of &lt;10 g/dL

          -  stroke within the previous 10 days

          -  documented hemorrhagic tendencies, or blood dyscrasias

          -  Renal insufficiency (serum creatinine level of 12.5 mg per deciliter or calculated
             creatinine clearance of &lt;50 ml per minute)

          -  Weight in excess of 325 pounds

          -  Resting hypotension (systolic blood pressure of &lt;90mmHg) or resting hypertension
             (systolic blood pressure of &gt;170mmHg or diastolic blood pressure of &gt;110 mmHg)

          -  History of active malignancy requiring concurrent chemotherapy

          -  Known allergy to iodinated contrast material

          -  pregnancy, women of childbearing potential unwilling to use adequate contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Budoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 16, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <results_first_submitted>August 6, 2018</results_first_submitted>
  <results_first_submitted_qc>March 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2019</results_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew J. Budoff</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>cardiac Computed tomography</keyword>
  <keyword>coronary calcification</keyword>
  <keyword>intervention</keyword>
  <keyword>warfarin</keyword>
  <keyword>apixaban</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Apixaban</title>
          <description>apixaban 5 mg or 2.5 mg po bid
apixaban: 5 po or 2.5 po bid.</description>
        </group>
        <group group_id="P2">
          <title>Warfarin</title>
          <description>warfarin with target INR of 2-3
warfarin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>all patients who were initially enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Apixaban</title>
          <description>apixaban 5 mg or 2.5 mg po bid
apixaban: 5 po or 2.5 po bid.</description>
        </group>
        <group group_id="B2">
          <title>Warfarin</title>
          <description>warfarin with target INR of 2-3
warfarin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="2.4"/>
                    <measurement group_id="B2" value="60" spread="1.9"/>
                    <measurement group_id="B3" value="57" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>coronary calcium</title>
          <units>participants with coronary calcium</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coronary Artery Calcium (CAC) Score</title>
        <description>amount of calcification measured by Agatston Score. The range of values for the Agatston score is 0-10000. Higher score is worse outcome.</description>
        <time_frame>1 year</time_frame>
        <population>all with follow up scans</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>apixaban 5 mg or 2.5 mg po bid
apixaban: 5 po or 2.5 po bid.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>warfarin with target INR of 2-3
warfarin</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Artery Calcium (CAC) Score</title>
          <description>amount of calcification measured by Agatston Score. The range of values for the Agatston score is 0-10000. Higher score is worse outcome.</description>
          <population>all with follow up scans</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" spread="129.9"/>
                    <measurement group_id="O2" value="31" spread="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coronary Plaque on CT Angiography</title>
        <description>To evaluate if treatment with apixaban therapy, as compared to warfarin therapy, will modify the progression, regression and stabilization of coronary atherosclerosis. Modifications will include differences in plaque volume, composition and arterial remodeling; as well as new atherosclerosis formation. The scale is based upon volume of plaque in the coronary arteries, with zero being no plaque and a higher number being more plaque. There is no scale or maximum measure, this is a linear measure of atherosclerosis volume in the coronary arteries and more is worse. None is best, any plaque is considered worse, and a higher plaque volume represents more atherosclerosis. An individual of average health will have a score of 50.</description>
        <time_frame>1 year</time_frame>
        <population>all participants with follow up data</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>apixaban 5 mg or 2.5 mg po bid
apixaban: 5 po or 2.5 po bid.</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>warfarin with target INR of 2-3
warfarin</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Plaque on CT Angiography</title>
          <description>To evaluate if treatment with apixaban therapy, as compared to warfarin therapy, will modify the progression, regression and stabilization of coronary atherosclerosis. Modifications will include differences in plaque volume, composition and arterial remodeling; as well as new atherosclerosis formation. The scale is based upon volume of plaque in the coronary arteries, with zero being no plaque and a higher number being more plaque. There is no scale or maximum measure, this is a linear measure of atherosclerosis volume in the coronary arteries and more is worse. None is best, any plaque is considered worse, and a higher plaque volume represents more atherosclerosis. An individual of average health will have a score of 50.</description>
          <population>all participants with follow up data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="52"/>
                    <measurement group_id="O2" value="54" spread="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 YEAR</time_frame>
      <desc>same as clinicaltrials.gov</desc>
      <group_list>
        <group group_id="E1">
          <title>Apixaban</title>
          <description>apixaban 5 mg or 2.5 mg po bid
apixaban: 5 po or 2.5 po bid.</description>
        </group>
        <group group_id="E2">
          <title>Warfarin</title>
          <description>warfarin with target INR of 2-3
warfarin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Matthew Budoff</name_or_title>
      <organization>Los Angeles Biomedical Research Institute at Harbo</organization>
      <phone>3102224107</phone>
      <email>mbudoff@labiomed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

